Secretin - ChiRhoClin

Drug Profile

Secretin - ChiRhoClin

Alternative Names: ChiRhoStim; Synthetic secretin diagnostics - ChiRhoClin

Latest Information Update: 08 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ChiRhoClin
  • Class Antipsychotics; Gastrointestinal hormones; Neuropeptides; Peptide diagnostics; Peptide hormones
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Exocrine pancreatic insufficiency; Pancreatic cancer
  • No development reported Pain
  • Discontinued Pancreatitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 09 Apr 2012 Registered for Pancreatic cancer (Diagnosis) in USA (IV)
  • 10 Aug 2004 Clinical studies have been added to the adverse events, pharmacokinetics and drug interaction sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top